Jiayi Yu,Junya Yan,Qian GUO,Zhihong Chi,Bixia Tang,Bin Zheng,Jinyu YU,Ting Yin,Zhiyuan Cheng,Xiaowei Wu,Huan Yu,Jie Dai,Xinan Sheng,Lu Si,Chuangliang Cui,Xue Bai,Lili Mao,Bin Lian,Xuan Wang,Xieqiao Yan,Siming Li,Li Zhou,Keith,Jun Guo and Yan Kong#.Genetic aberrations in the CDK4 pathway sssociated with innate resistance to PD-1 blockade in Chinese patients with non-cutaneous melanoma,Clin Cancer Res,25(21): 6511-6523

Yang L,?Dai J,?Ma M,?Mao L,?Si L,?Cui C,?Sheng X,?Chi Z,?Yu S,?Xu T,?Yu J,?Kong Y,?Guo J.Identification of a functional polymorphism within the 3'-untranslated region of denticleless E3 ubiquitin protein ligase homolog associated with survival in acral melanoma..Sep;1,Eur J Cancer,118:70-81

Felicity Newell,Yan Kong#,James Wilmott,Peter Johansson,Peter Ferguson,Chuangliang Cui,Zhongwu Li,Stephen Kazakoff,Hazel Burke,Tristan Dodds,Ann-Marie Patch,Katia Nones,Varsha Tembe,Ping Shang,Louise van der Weyden,Kim Wong,Oliver Holmes,Serigne Lo,Conrad Leonard,Scott Wood,Qinying Xu,Robert Rawson,Pamela Mukhopadhyay,Reinhard Dummer,Mitchell Leesque,,Goran Jonsson,Xuan Wang,lwei Yeh,Hong Wu,Nancy Joseph,Boris Bastian,Georgina Long,Andrew Spillane,Kerwin Shannon,John Thompson,Robyn Saw,David Adams,Lu Si,John Pearson,Nicholas Hayward,Nicola Waddell,Graham,Jun Guo,and Richard Scolyer.Whole-genome landscape of mucosal melanoma reveals diverse and therapeutic targets,Nature Conmunication,10(1):3163

Yu J,?Xu L,?Yan J,?Yu J,?Wu X,?Dai J,?Guo J,?Kong Y# .MUC4 isoforms expression profiling and prognosis value in Chinese melanoma patients,Clin Exp Med,22(20);299-311

Dai J,?Yang L,?Xu T,?Si L,?Cui C,?Sheng X,?Chi Z,?Mao L,?Lian B,?Tang B,?Bai X,?Zhou L,?Li S,?Wang X,?Yan X,?Kong Y#,?Guo J.A Functional Synonymous Variant in?PDGFRA?Is Associated with Better Survival in Acral Melanoma,J Cancer,11(10):2945-2956

Yu J,?Yu J,?Wu X,?Guo Q,?Yin T,?Cheng Z,?Dai J,?Kong Y,?Guo J.The TERT copy number gain is sensitive to telomerase inhibitors in human melanoma.Clin Sci (Lond),Clin Sci (Lond),134(2):193-205

Yan J, Xu L, Yu J, Wu X, Dai J, Xu T, Yu H, Guo J,Kong Y# . Prognostic role of NRAS isoforms in Chinese melanoma patients,Melanoma research,29(3):263-269

Huan Tang,Meng Ma,Jie Dai,Chuanliang Cui,Lu Si,Xinan Sheng,Zhihong Chi,Longwen XU,Sifan Yu,Tianxiao Xu,Junya Yan,Huan Yu,Lu Yang,Yan Kong# and Jun Guo.miR-let-7b and miR-let-7c suppress tumourigenesis of human mucosal melanoma and enhance the sensitivity to chemotherapy.,J Exp Clin Cancer Res,38(1):212

Ma M, Dai J, Tang H, Xu T, Yu S, Si L, Cui C, Sheng X, Chi Z, Mao L, Wu X, Yang L, Yu H, Li S, Lian B, Tang B, Wang X, Yan X, Bai X, Zhou L,Kong Y* and Guo J*. MicroRNA-23a-3p Inhibits Mucosal Melanoma Growth and Progression through Targeting Adenylate Cyclase 1 and Attenuating cAMP and MAPK Pathways.,Theranostics,9(4): 945-960

Yu J, Wu X, Yan J, Yu J, Yin T，Dai J, Ma M, Xu T, Yu H, Xu L,Yang L,Cheng Z, Chi Z, Sheng X, Cui C, Guo J*, Kong Y*, potential mutations in uveal melanoma identified using targeted nest-generation sequencing.,Journal of Cancer,10(2):488-493

Yan J, Wu X, Yu J, Ma M, Yu H, Xu T, Tang H, Xu L, Dai J, Si L, Chi Z, Sheng X, Cui C, Guo J*, Kong Y*. Establishment and characterization of melanoma patient-derived xenograft models for preclinical evaluation of novel therapeutics.,Melanoma research,28(6):527-35

Xiaowen Wu, Jiayi Yu, Junya Yan, Jie Dai, Lu Si, Zhihong Chi, Xinan Sheng, Chuanliang Cui, Meng Ma, Huan Tang, Tianxiao Xu, Huan Yu, Yan Kong* & Jun Guo* PI3K/AKT/mTOR pathway inhibitors inhibit the growth of melanoma cells with mTOR H2189Y mutations in vitro,Cancer biology & therapy,19(7):584-589

Yu S, Xu T, Dai J, Ma M, Tang H, Chi Z, Si L, Cui C, Sheng X, Kong Y* and Guo J*. TERT copy gain predicts the outcome of high-dose interferon α-2b therapy in acral melanoma.,Onco Targets and Therapy,17;11:4097-4104

Xu T, Ma M, Dai J, Yu S, Wu X, Tang H, Yu J, Yan J, Yu H, Chi Z, Si L, Sheng X, Cui C, Kong Y* and Guo J.Gene expression screening identifies CDCA5 as a potential therapeutic target in acral melanoma,Hum Pathol,75:137-145.

Yu J, Yu H, Yan J, Wu X, Yang L, Dai J, Ma M, Tang H, Xu T, Chi Z, Si L, Sheng X, Cui C, Guo J*, Kong Y*. Methylation of O6-Methylguanine DNA Methyl transferase is a predictive biomarker in Chinese melanoma patients treated with alkylating agents.,Translational Cancer Research,

Tianxiao Xu,Meng Ma,Zhihong Chi,Lu Si,Xinan Sheng,Chuanliang Cui, Jie Dai,Sifan Yu ,Junya Yan ,Huan Yu ,Xiaowen Wu ,Huan Tang ,Jiayi Yu ,Yan Kong* ,Jun Guo* High G2 and S-phase expressed 1 expression promotes acral melanoma progression and correlates with poor clinical prognosis,Cancer Science,

Xu T, Yu S, Ma M, Dai J, Chi Z, Si L, Sheng X, Cui C, Kong Y* and Guo J*. cMET-N375S germline mutation is associated with poor prognosis of melanoma in Chinese patients.,Translational Cancer Research,7(2):248-256

Junya Yan, Jiayi Yu, Xiaowen Wu, Tianxiao Xu, Huan Yu, Jie Dai, Meng Ma, Huan Tang, Longwen Xu, Zhihong Chi, Lu Si, Xinan Sheng, Chuanliang Cui, Yan Kong*, Jun Guo* Increased AURKA Gene Copy Number Correlates with Poor Prognosis and Predicts the Efficacy of High-dose Interferon Therapy in Acral Melanoma,Journal of Cancer,9(7):1267-1276

Meng Ma,Jie Dai,Tianxiao Xu,Sifan Yu,Huan Yu,Huan Tang,Junya Yan,Xiaowen Wu,Jiayi Yu,Zhihong Chi,Lu Si,Chuanliang Cui,Xinan Sheng,Yan Kong* and Jun Guo*.Analysis of TSC1 mutation spectrum in mucosal melanoma.,J Cancer Res Clin Oncol,144(2):257-267

Junya Yan，Xiaowen Wu，Jiayi Yu，Huan Yu，Tianxiao Xu，Kevin M Brown，Jie Dai，Meng Ma，Huan Tang，Lu Si， Zhihong Chi，Xinan Sheng，Chuanliang Cui，Yan Kong*，Jun Guo*.Analysis of NRAS gain in 657 patients with melanoma and evaluation of its sensitivity to a MEK inhibitor.,Eur J Cancer,89:90-101

Yu J, Wu X, Yan J, Yu H, Xu L, Chi Z, Sheng X, Si L, Cui C, Dai J, Ma M, Xu T, Kong Y* and Guo J*.Anti-GD2/4-1BB chimeric antigen receptor T cell therapy for the treatment of Chinese melanoma patients,Journal of hematology & oncology,11(1):1-15

Yu H, Ma M, Yan J, Xu L, Yu J, Dai J, Xu T, Tang H, Wu X, Li S, Lian B, Mao L, Chi Z, Cui C, Guo J* Kong Y*. Identification of coexistence of BRAF V600E mutation and EZH2 gain specifically in melanoma as a promising target for combination therapy,Journal of translational medicine,15(1):243

Kong Y★, Sheng X, Wu X, Yan J, Ma M, Yu J, Si L, Chi Z, Cui C, Dai J, Li Y, Yu H, Xu T, Tang H, Tang B, Mao L, Lian B, Wang X, Yan X, Li S, Guo J. Frequent Genetic Aberrations in the CDK4 Pathway in Acral Melanoma Indicate the Potential for CDK4/6 Inhibitors in Targeted Therapy,Clin Cancer Res,23(22):6946-6957

Bai X, Kong Y★, Chi Z, Sheng X, Cui C, Wang X, Mao L, Tang B, Li S, Lian B, Yan X, Zhou L, Dai J, Guo J, Si L.MAPK Pathway and TERT Promoter Gene Mutation Pattern and Its Prognostic Value in Melanoma Patients: A Retrospective Study of 2,793 Cases,Clin Cancer Res,23(20):6120-6127

Yu J, Wu X, Yu H, Li S, Mao L, Chi Z, Si L, Sheng X, Cui C, Dai J, Ma M, Tang H, Xu T, Yan J, Kong Y#, Guo J. Systemic Immune-Inflammation Index and Circulating T-Cell Immune Index Predict Outcomes in High-Risk Acral Melanoma Patients Treated with High-Do se Interferon,Transl Oncol,10(5):719-725

Xiaowen Wu, Junya Yan, Jie Dai, Meng Ma, Huan Tang, Jiayi Yu, Tianxiao Xu, Huan Yu, Lu Si, Zhihong Chi, Xinan Sheng, Chuanliang Cui, Yan Kong*, and Jun Guo*.Mutations in BRAF codons 594 and 596 predict good prognosis in melanoma.,Oncology letters,14(3):3601-3605

Dai J, Wu S, Kong Y★, Chi Z, Si L, Sheng X, Cui C, Fang J, Zhang J, Guo J. Nanosecond Pulsed Electric Fields Enhance the Anti-tumour Effects of the mTOR Inhibitor Everolimus against Melanoma,Sci Rep,7:39597

Sheng X, Kong Y★, Li Y, Zhang Q, Si L, Cui C, Chi Z, Tang B, Mao L, Lian B, Wang X, Yan X, Li S, Dai J, Guo J.GNAQ and GNA11 mutations occur in 9.5% of mucosal melanoma and are associated with poor prognosis,Eur J Cancer,;65:156-63

Kong Y★, Si L, Li Y, Wu X, Xu X, Dai J, Tang H, Ma M, Chi Z, Sheng X, Cui C, Guo J. Analysis of mTOR Gene Aberrations in Melanoma Patients and Evaluation of Their Sensitivity to PI3K-AKT- mTOR Pathway Inhibitors,Clin Cancer Res,22; 4:1018-1027

功能性人工免疫分子的临床前研究, 参加者 , 2020.5.18～2024.12.31, 国家重点研发计划

TERT高拷贝介导PD-1单抗治疗肢端型黑色素瘤耐药的作用机制研究, 课题负责人 , 2020.1.1～2022.12.31, 北京市自然科学基金

EZH2介导的CRTAC1沉默在粘膜型黑色素瘤发展中的作用及其临床意义, 课题负责人 , 2019.8.16～2023.12.31, 国家自然科学基金

肢端及粘膜型黑色素瘤肿瘤特异性新抗原鉴定及个体化多肽疫苗的抗肿瘤作用研究, 课题负责人 , 2019.8.1～2023.8.31, 首都临床诊疗技术研究及示范应用专项

粘膜型黑色素瘤中DGKζ的功能及其作为潜在治疗靶点的研究, 课题负责人 , 2017.1.1～2021.12.31, 国家自然科学基金面上项目

基于驱动基因筛查的肢端及粘膜型黑色素瘤精准治疗模式, 课题负责人 , 2015.12.1～2018.12.31, 北京市卫生系统高层次卫生技术人才队伍建设工程

研究生招生计划

招生年度	招生专业	学位级别	学位类型	研究方向	选拔方式
2021	肿瘤学	硕士	科学学位	肿瘤分子标志物与个体化治疗	全国统考